ACCE price target published on 15 Oct 2026, 00:00 CEST; previously $2.00 since 28 Sept 2026, 00:00 CEST.
Price used: $7.67 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net asset value and Discounted cash flow.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
18
out of 100
P/E
0.0x
forward 0.0x
1-year return
-52.1%
Dividend yield
0.00%
Regencell Bioscience Holdings Limited Ordinary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Regencell Bioscience is a Hong Kong based company developing traditional Chinese medicine formulations for neurological conditions such as ADHD and autism spectrum disorder. It has no revenue and no commercial product. The only catalyst is clinical and regulatory progress, which is slow and uncertain. With a market cap of 3.5B USD, a ROE of -128.5% and no sales, the valuation rests entirely on expectations rather than any financial result.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
severe
Negative earnings and cash burn
ROE of -128.5%, negative FCF of $6.2M annually, and zero profitability across all margins signal ongoing losses and cash consumption.
severe
Valuation metrics collapse
P/E, forward P/E, and P/S all show 0.0; EV/EBITDA of -323.8 indicates the company is unprofitable and model-derived fair value ($2.00) is 73% below current price ($7.35).
high
Stalled revenue and growth
YoY revenue growth at 0.0%, earnings YoY at 0.0%, and no 5-year CAGR data available suggest the business is not expanding.
moderate
Minimal institutional support
Institutional ownership at 0.3% with insider concentration at 88.3% leaves little external validation or liquidity cushion.
AI research notes
AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-09-30 · prices to Oct 23, 2026
Why it could do well
Balance sheet is fortress-like with debt to equity of just 0.02, providing substantial financial flexibility.
Share count held flat year over year at 0.0% dilution, protecting existing shareholders from equity issuance.
Stock trades at $7.35 with minimal cash burn relative to market cap, suggesting downside is limited.
Why it could disappoint
Company burned $6M in free cash flow over the last 12 months with zero revenue growth.
Return on equity of negative 128.5% shows the business destroys shareholder value at an alarming rate.
Net margin sits at 0.0% with negative 70.6% return on invested capital, indicating no viable path to profitability.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Oct 30, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where RGC's valuation models land
Price
$7.67
Model fair valueConfidence: low
about $2.29
Model
Fair value
Upside
Net asset value
Discounted cash flow
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.